First clinical study of BioRestorative Therapies' brtxDISC stem cell therapy for protruding or bulging lumbar discs

Trial Profile

First clinical study of BioRestorative Therapies' brtxDISC stem cell therapy for protruding or bulging lumbar discs

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Intervertebral disc stem cell replacement therapy BioRestorative Therapies (Primary)
  • Indications Back pain; Intervertebral disc degeneration
  • Focus Adverse reactions
  • Sponsors BioRestorative Therapies
  • Most Recent Events

    • 08 Feb 2017 According to a BioRestorative Therapies media release, company received clearance by the U.S. Food and Drug Administration (FDA) to commence this study.
    • 09 Jan 2017 According to a BioRestorative media release, company has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to seek clearance to commence this trial using its lead cell therapy candidate, BRTX-100, to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs.
    • 09 Feb 2016 According to a BioRestorative media release, planned initiation date changed from 1 Dec 2015 to 1 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top